Additionally, in the KEYNOTE-122 study, PD-L1 expression, using a combined positive score (including tumor and immune cells) at cut-offs of 1%, 10%, and 20%, did not appear to correlate with a PFS advantage for pembrolizumab monotherapy in patients with platinum-pretreated r/m NPC [45]. The gene discussed is CD274; the disease is nasopharyngeal carcinoma.